Company intelligence / Profile preview
OrthoSera
- Ownership
- Private
- Employees
- ~24
- Development stage
- Commercial
Overview
OrthoSera has commercialized its albumin-coated bone allograft product BoneAlbumin™ in Europe with demonstrated clinical benefit in orthopedic and dental applications. Its next-generation hyperacute serum therapy hypACT™ has shown promising results compared to PRP and other blood derivatives in osteoarthritic tissue models and is being clinically administered with ongoing data collection. The company also develops point-of-care devices for autologous serum production.
Clinical studies have shown improved outcomes with their products over several years of follow-up.- Therapeutic areas
- OtherDermatologyInfectious DiseasesRheumatology
- Modalities
- Blood derivatives (serum-based therapies)Albumin-coated bone allograftsAutologous serum productsHyperacute serum (hypACT™)
- Industry
- Biotech
Drug pipeline
2 assets1 more asset in the full pipeline.
Partnerships
Beyond the preview
Go deeper on OrthoSera.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OrthoSera.